Background The establishment of the Cancer Drugs Fund (CDF), which removed the necessity for cost-effectiveness as a criterion for drugs access and expedited access to nonNICE appraised drugs, has significantly changed prescribing of cancer drugs for terminally ill cancer patients in the NHS. Neither clinicians nor the public have a preference for spending money on cancer over other disease sta...

breast cancer is the leading cause of malignancy among women. screening using mammography is proposed as an effective intervention for reducing early deaths due to breast cancer. we conducted a systematic review to assess the cost-effectiveness of such screening programs. we searched medline, scopus and google scholar and complemented it by other searches using sensitive search terms from 1993-...

Abstract Molecular targeted therapies and immune checkpoint inhibitors have in recent years been transforming the care of many cancer patients. This chapter compares twenty-one appraisals molecular non-small-cell lung cancer, comprising six EGFR-TK (gefitinib, erlotinib, afatinib, necitumumab, osimertinib dacomitinib), five ALK (crizotinib, ceritinib, alectinib, brigatinib lorlatinib) two ROS1 ...

BACKGROUND An estimated $8.1 billion (in 2004 dollars) is spent annually on total health care costs for the treatment of breast cancer in the United States. Breast cancer has traditionally been treated with intravenous (IV) cancer therapies that entail not only the drug acquisition cost, but additional costs of personnel time, supplies, and equipment used in the preparation and administration o...

The Cancer Drug Fund was originally conceived as a temporary measure, until value based pricing for drugs was introduced, to give NHS cancer patients access to drugs not approved byNICE. Spending on these drugs rose from less than the £50m (€63m; $79m) budgeted for the first year in 2010-11 to well over £200m in 2013-14, and the budget for the scheme—now extended for a further two years—will re...

The WHO has previously produced recommendations on the essential drugs required for cancer therapy. Over the last five years several new anti cancer drugs have been aggressively marketed. Most of these are costly and produce only limited benefits. We have divided currently available anti-cancer drugs into three priority groups. Curable cancers and those cancers where the cost-benefit ratio clea...

Most cancer drugs recently entering the European market do so without clear evidence of extending or improving quality of life, new research published in The BMJ has found. The findings raise serious questions about why the current regulatory environment supports the approval of cancer drugs that may leave patients at risk of experiencing toxicity and reduced quality of life without deriving me...